Advances in the quantitation of therapeutic insulin analogues by LC-MS/MS

Bioanalysis

Volumn 5, Issue 23, 2013, Pages 2933-2946

  Blackburn, Michael ^a  

^a Department of Genetic and Molecular Toxicology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BAGVAERD; BIOSIMILAR AGENT; C PEPTIDE; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; PROINSULIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; BIOSYNTHESIS; CARBOXY TERMINAL SEQUENCE; CHROMATOGRAPHY; CLINICAL RESEARCH; CROSS REACTION; DOPING; ENZYME LINKED IMMUNOSORBENT ASSAY; FORENSIC MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RECEPTOR BINDING ASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; STANDARD; TANDEM MASS SPECTROMETRY; TOXICOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY;

EID: 84890371304     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.257     Document Type: Review

References (73)

1. Rosenfeld L. Insulin: Discovery and controversy. Clin. Chem. 48(12), 2270-2288 (2002
2. Oldfield P. A wide angle view of biosimilars from a bioanalytical perspective. Bioanalysis 5(5), 533-535 (2013
3. Bowsher R, Nowatzke W. Insights in regulated bioanalysis of human insulin and insulin analogues by immunoanalytical methods. Bioanalysis 3(8), 883-898 (2011
4. Johnson IS. Human insulin from recombinant DNA technology. Science 219(4585), 632-637 (1983
5. IMAP Healthcare. Pharmaceuticals & Biotech Industry Global Report - 2011. IMAP, Istanbul, Turkey (2011
6. Cai XY, Wake A, Gouty D. Analytical and bioanalytical assay challenges to support comparibility studies for biosimilar drug development. Bioanalysis 5(5), 517-520 (2013
7. Yalow R, Berson S. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 39(7), 1157-1175 (1960
8. Owen WE, Roberts WL. Cross-reactivity of three recombinant isulin analogs with five commercial insulin assays. Clin. Chem. 50(1), 257-259 (2004
9. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of 11 human insulin assays: Implications of clinical investigation and research. Clin. Chem. 53 (5), 922-932 (2007
10. American Diabetes Association. Insulin Assay Standardisation Project. American Diabetes Association, VA, USA (2006
11. Thevis M, Thomas A, Schanzer W. Mass spectrometric determination of insulins and their degradation products in sports drugs testing. Mass Spectrom. Rev. 27(1), 35-50 (2008
12. Koster C, Castoro J, Wilkins C. High-resolution matrix-assisted laser desorption/ionization of biomolecules by Fourier transform mass spectrometry. J. Am. Chem. Soc. 114(19), 7572-7574 (1992
13. Colby S, King T, Reilly J, Lubman D. Improving the resolution of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry by exploiting the correlation between ion position and velocity. Rapid Commun. Mass Spectrom. 8(11), 865-868 (2005
14. De Hoffmann E, Stroobant V. Quadrupole analysers. In: Mass Spectrometry, Principles and Applications. John Wiley & Sons Ltd, Chichester, UK, 85-98 (2007
15. Rogatsky E, Balent B, Goswami G et al. Sensitive quantitative analysis of C-peptide in human plasma by 2-dimensional liquid chromatography-mass spectrometry isotope-dilution assay. Clin. Chem. 52(5), 872-879 (2006
16. Chambers E, Legido-Quigley C, Smith N, Fountain K. Development of a fast method for direct analysis of intact synthetic insulins in human plasma: The large peptide challenge. Bioanalysis 5(1), 65 - 81 (2013
17. Tuthill CW, Rudolph A, Li Y et al. Quantitative analysis of thymosin a1 human serum by LC-MS/MS. AAPS PharmSciTech 1(2), 37-44 (2000
18. Biemann K. Contributions of mass spectrometry to peptide and protein structure. Biomed. Environ. Mass Spectrom. 16(1-2), 99-111 (1988
19. Roerpstorff P, Fohlmann J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed. Mass Spectrom. 11(11), 601 (1984
20. De Hoffmann E, Stroobant V. Proteins and peptides. In: Mass Spectrometry, Principles and Applications. John Wiley & sons Ltd, Chichester, UK, 305-341 (2007
21. Loo J, Edmonds C, Smith R. Tandem mass spectrometry of very large molecules. 2. Dissociation of multiply charged proline-containing proteins from electrospray ionisation. Anal. Chem. 65(4), 425-438 (1993
22. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W. Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography tandem mass spectrometry. Anal. Chem. 78(6), 1897-1903 (2006
23. Blackburn M, Bell B, Gray N, Schmidt R, Schmidt D, McDougall S. Quantitation of a therapeutic insulin analogue by immuno-affinity extraction - LC-MS/MS. Presented at: European Bioanalytical Forum 5th Open Meeting. Barcelona, Spain, 14-16 November 2012
24. Thevis M, Schanzer W. Mass spectrometric identification of peptide hormones in doping control analysis. Analyst 132(4), 287-291 (2007
25. Rahn G, Miller G, Branch T, Parish T, Davey L. Accomplishing trace level quantitation during bioanalytical method development of a large peptide. Proceedings of: The 54th ASMS Conference on Mass Spectrometry and Allied Topics. Seattle, WA, USA, 28 May-1 June 2006
26. Chen Z, Caulfield MP, McPhaul M, Reitz R, Taylor S, Clarke N. Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin. Chem. 59(9), 1349-1356 (2012
27. Li F, Fast D, Michael S. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis 3(21), 2459-2480 (2011
28. Thomas A, Schänzer W, Delahaut P, Thevis M. Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nano-UPLC coupled with high-resolution/high-accuracy mass spectrometry. Drug Test. Anal. 1(5), 219-227 (2009
29. Chen J. Bioanalytical quantitation of biotherapeutics using intact protein vs proteolytic peptides by LC-HR/AM on a Q-Exactive MS. Presented at: 61st ASMS Conference on Mass Spectrometry and Allied Topics. Minneapolis, MN, USA, 9-13 June 2013
30. Magnes C, Gatschelhofer C, Pickl K, Pieber T, Sinner F. Strategies for quantification of insulin and insulin analogues by LC-MS/MS. Presented at: 52nd ASMS Conference on Mass Spectrometry and Allied Topics. Nashville, TN, USA, 23-27 May 2004
31. Klaasen T, Szwandt S, Kapron JT, Roemer A. Validated quantitation method for a peptide in rat serum using liquid chromatograph/high field asymmetric waveform ion mobility spectrometry. Rapid Commun. Mass Spectrom. 23(15), 2301-2306 (2009
32. Moody D, Laycock J, Spanbauer A et al. Determination of buprenorphine in human plasma by gas chromatography-positive ion chemical ionization mass spectrometry and liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 21(6), 406-414 (1997
33. Wachtel DT, Forsyth ST, Busby RW. Differential Mobility Separation Mass Spectrometry for Quantitation of Large Peptides in Biological Matrices. ABSciex, Framingham, MA, USA (2012
34. Thevis M, Thomas A, Schänzer W. Doping control analysis of selected peptide hormones using LC-MS (/MS). Forensic Sci. Int. 213(1), 35-41 (2011
35. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12), 1379-1397 (2011
36. Stevenson D. Immuno-affinity solid phase extraction. J. Chromatogr. B Biomed. Sci. Appl. 745(1), 39-48 (2000
37. Ackermann B. Hybrid imunoaffinity-mass spectrometric methods for efficient protein biomarker verification in pharmaceutical development. Bioanalysis 1(2), 265-268 (2009
38. Becker J, Hoofnagle A. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. Bioanalysis 4(3) 281-290 (2012
39. Kuuranne T, Thomas A, Leinonen A et al. Insulins in equine urine: Qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse racing. Rapid Commun. Mass Spectrom. 22(3), 355-362 (2008
40. Ho E, Wan T, Wong A, Lam K, Stewart, B. Doping control analysis of insulin and its analogues in equine plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A, 1201(2), 183-190 (2008)..
41. Tsikas D. Quantitative analysis of biomarkers, drugs and toxins in biological samples by immunoaffinity chromatography coupled to mass spectrometry or tandem mass spectrometry: A focused review of recent applications. J. Chromatogr. B 878(2), 133-148 (2010
42. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W. Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal. Chem. 77(11), 3579-3585 (2005
43. Bolli GB, Hahn A, Schmidt R et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with Type 1 diabetes. Diabetes Care 35(12), 2626-2630 (2012
44. Oran P, Jarvis J, Borges C, Sherma N, Nelson R. Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin. Appl. 5(7-8), 454-459 (2011
45. Niederkofler E, Nedelkov D, Kiernan U et al. Integrated targeted quantitative method for insulin and its therapeutic analogs. Presented at: 61st ASMS Conference on Mass Spectrometry and Allied Topics. Minneapolis, MN, USA, 9-13 June 2013
46. Darby S, Miller M, Allen R, LeBeau M. A mass spectrometric method for quantitation of intact insulin in blood samples. J. Anal. Toxicol. 25(1), 8-14 (2001
47. Hess C, Thomas A, Thevis M et al. Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 404(6-7), 1813-1822 (2012
48. Fountain K, Chambers E, Smith N, Legido-Quigley C. Development of an SPE-LC-MS/MS method for simultaneous quantification of intact human insulin and 5 analogs in human plasma. Presented at: HPLC 39th International Symposium on High Performance Liquid Phase Separations and Related Techniques. Amsterdam, The Netherlands, 16-20 June 2013
49. Havard G, Marcoux MJ, Lachance S, Boudreau N, Levesque A. Ability to measure human insulin by LC-MSMS. Program and abstracts of the European Bioanalytical Forum 5th Open Meeting. Barcelona, Spain, 14-16 November 2012 (Poster
50. Yilmaz B, Kadioglu Y, Kafkas. Determination of insulin in rabbit plasma using high performance liquid chromatography. Kafkas Univ. Vet. Fak. Derg. 18(1), 31-36 (2012
51. Campbell JL, Le Blanc JY. Peptide and protein drug analysis by MS: Challenges and opportunities for the discovery environment. Bioanalysis 3(6), 645-657 (2011
52. Widmark EM. Observations on the solubility of insulin. Biochem. J. 17(4-5), 668-670 (1923
53. Kippen A, Cerini F, Vadas L et al. Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and type II diabetic individuals with comparison to immunoassay. J. Biol. Chem. 272(19), 12513-12522 (1997
54. van den Broek I, Sparidans R, Schellens J, Beijnen J. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B 872(1), 1-22 (2008
55. Van Uytfanghe K, Rodriguez-Cabalero D, Stockl D, Thienpont L. New liquid chromatography/electrospray tandem mass spectrometry measurement procedure for quantitative analysis of human insulin in serum. Rapid Commun. Mass Spectrom. 21(5), 819-821 (2007
56. Kay R, Roberts A. Bioanalysis of biotherapeutic proteins and peptides: Immunological or MS approach? Bioanalysis 4(8), 857-860 (2012
57. Sonksen P. Insulin growth hormone and sport. J. Endocrinol. 170(1), 13-15 (2001
58. International Olympic Committee. List of Prohibited Classes of Substances and Prohibited Methods of Doping. International Olympic Committee, Lausanne, Switzerland (2003
59. Haibach H, Dix J, Shah J. Homicide by insulin administration. J. Forensic Sci. 32(1), 208-216 (1987
60. Thomas A, Schanzer W, Delahaut P, Thevis M. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. Methods 56(2), 230-235 (2012
61. Ho E, Wan T, Wong A, Lam K, Stewart B. Doping control analysis of insulin and its analogues in equine urine by liquid chromatography-tandem mas sspectrometry. J. Chromatogr. A 1218, 1139-1146 (2011
62. Kuerzel G, Shukla U, Scholtz H et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr. Med. Res. Opin. 19(1), 34-40 (2003
63. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: In vitro appraisal with human insulin immunoassay. Diabetes Metab. 33(3), 205-212 (2007
64. Guide for Validation of Analytical and Bioanalytical Methods. Resolution - RE n. 899, of May 29, 2003. Agência Nacional de Vigilância Sanitária, Brasilia, Brazil (2003
65. Timmerman P, Lausecker B, van Amsterdam P, Luedtke S, Dijksman J. Large meets small: Connecting the bioanalytical community around peptide and protein bioanalysis with LC-MS(/MS). Bioanalysis 4(6), 627-631 (2012
66. Thevis M, Loo J, Loo R, Schänzer W. Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing. Rapid Commun. Mass Spectrom. 21(3), 297-304 (2007
67. Rodriguez-Cabalero D, Van Uythange K, Stove V, Fiers T, Thienpont L. Pilot study for the standardization of insulin immunoassays with isotope dilution - liquid chromatography/mass spectrometry. Clin. Chem. 53(8), 1462-1469 (2007
68. Heinig K, Wirz T, Schick E, Guenzi A. Bioanalysis of therapeutic peptides: Total, free, protein bound, anti-drug antibody bound drug - what should we measure, what can we measure? Program and Abstracts of the European Bioanalytical Forum 5th Open Meeting. Barcelona, Spain, 14-16 November 2012
69. Gennaro WD, Van Norman JD. Quantitation of free, total, and antibody-bound insulin in insulin-treated diabetics. Clin. Chem. 21(7), 873-879 (1975
70. Korfmacher W. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures. Bioanalysis 3(11), 1169-1171 (2011
71. Xia YQ, Wu ST, Jemal M. LC-FAIMS-MS/MS for quantification of a peptide in plasma and evaluation of FAIMS global selectivity from plasma components. Anal. Chem. 80(18), 7137-7143 (2008
72. Campbell JL, Le Blanc JC. Using high resolution quadrupole TOF technology in DMPK analyses. Bioanalysis 4(5), 487-500 (2012
73. Plumb R, Fujimot G, Mather J et al. Comparison of the quantification of a therapeutic protein using nominal and accurate mass MS/MS. Bioanalysis 4(5), 605-615 (2012